Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The debt to equity ratio is 0.00 as of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly debt to equity ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00.
DEBT TO EQUITY RATIO
0.00
DEBT TO EQUITY RATIO AVG TTM
0.00
DEBT TO EQUITY RATIO AVG 3Y
0.00
DEBT TO EQUITY RATIO AVG 5Y
0.00
DEBT TO EQUITY RATIO AVG 10Y
N/A
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.13
median of 528 covered companies
CURRENT VS SECTOR MEDIAN
-100.00%
vs the sector median at left
Korsana Biosciences, Inc.
Market Cap
$146.64M
Debt to Equity Ratio
0.00
TTM Avg
0.00
3Y Avg
0.00
5Y Avg
0.00
Market Cap
$139.94M
Debt to Equity Ratio
0.00
TTM Avg
0.01
3Y Avg
0.01
5Y Avg
50.25
Market Cap
$147.54M
Debt to Equity Ratio
0.00
TTM Avg
0.02
3Y Avg
0.02
5Y Avg
0.01
Market Cap
$145.11M
Debt to Equity Ratio
0.55
TTM Avg
0.30
3Y Avg
0.18
5Y Avg
0.12
Market Cap
$144.48M
Debt to Equity Ratio
0.02
TTM Avg
0.06
3Y Avg
0.05
5Y Avg
0.05
Market Cap
$152.04M
Debt to Equity Ratio
0.00
TTM Avg
0.01
3Y Avg
0.01
5Y Avg
0.01
Market Cap
$140.05M
Debt to Equity Ratio
0.18
TTM Avg
0.22
3Y Avg
0.21
5Y Avg
0.14
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Korsana Biosciences, Inc. (KRSA) | $146.64M | 0.00 | 0.00 | 0.00 | 0.00 |
| Alpha Cognition Inc (ACOG)vs › | $139.94M | 0.00 | 0.01 | 0.01 | 50.25 |
| NervGen Pharma Corp. Common stock (NGEN)vs › | $147.54M | 0.00 | 0.02 | 0.02 | 0.01 |
| Acumen Pharmaceuticals, Inc. (ABOS)vs › | $145.11M | 0.55 | 0.30 | 0.18 | 0.12 |
| Immuneering Corporation (IMRX)vs › | $144.48M | 0.02 | 0.06 | 0.05 | 0.05 |
| Cardiol Therapeutics Inc. (CRDL)vs › | $152.04M | 0.00 | 0.01 | 0.01 | 0.01 |
| LifeMD, Inc. (LFMDP)vs › | $142.72M | 0.76 | 0.27 | 2.83 | 1.63 |
| Codexis, Inc. (CDXS)vs › | $152.20M | 2.20 | 1.17 | 0.71 | 0.54 |
| KORU Medical Systems, Inc. (KRMD)vs › | $140.05M | 0.18 | 0.22 | 0.21 | 0.14 |
| Anavex Life Sciences Corp. (AVXL)vs › | $152.45M | 0.00 | 0.00 | 0.00 | 0.00 |
Debt/Equity
0.00
Current Ratio
0.82
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | 0.00 |
| 2026-03-31 | 0.00 |
| 2025-12-31 | 0.00 |
| 2025-09-30 | 0.00 |
| 2025-06-30 | 0.00 |
| 2025-03-31 | 0.00 |
| 2024-12-31 | 0.00 |
| 2024-09-30 | 0.00 |
| 2024-06-30 | 0.00 |
| 2024-03-31 | 0.00 |
| 2023-12-31 | 0.00 |
| 2023-09-30 | 0.00 |
| 2023-06-30 | 0.00 |
| 2023-03-31 | 0.00 |
| 2022-12-31 | 0.00 |
| 2022-09-30 | 0.00 |
| 2022-06-30 | 0.00 |
| 2022-03-31 | 0.00 |
| 2021-12-31 | 0.00 |
| 2021-09-30 | 0.06 |
| 2021-06-30 | 0.05 |
| 2021-03-31 | 0.93 |
| 2020-12-31 | 0.77 |
| 2020-09-30 | 0.62 |
| 2020-06-30 | 0.80 |
| 2020-03-31 | 0.61 |
| 2019-12-31 | 0.76 |
| 2019-09-30 | 0.63 |
| 2019-06-30 | 0.52 |
| 2019-03-31 | 0.00 |
| 2018-12-31 | 0.00 |
| 2018-09-30 | 0.00 |
| 2018-06-30 | 0.00 |
| 2018-03-31 | 0.00 |
| 2017-12-31 | 0.00 |
| 2017-09-30 | 0.00 |
